Healthcare · Profile from Healthcare Research Companion
Koninklijke Philips N.V. (Royal Philips)
The Dutch light-bulb maker that spent three decades turning itself from a sprawling electronics conglomerate into a pure health-technology company, then suffered one of the most damaging recalls in medical device history. Philips sells MRI, CT, ultrasound and image-guided therapy systems, patient monitoring, sleep and respiratory devices and consumer health products (Sonicare toothbrushes, shavers). In June 2021 its Respironics unit recalled millions of CPAP, BiPAP and ventilator devices because their sound-abatement foam could break down. The recall, the litigation and a 2024 US consent decree erased most of the company's market value, cost roughly €5bn or more in provisions, impairments and settlements, removed Philips from new US sleep-device sales and forced a leadership change and restructuring.
At a glance
- Founded
- 15 May 1891, Eindhoven, Netherlands, by Gerard Philips and his father Frederik; Anton Philips joined in 1895
- Founders
- Gerard Philips, Frederik Philips; Anton Philips (commercial leader)
- Headquarters
- Amsterdam, Netherlands (historic home: Eindhoven)
- Ownership / structure
- Public company, Euronext Amsterdam (PHIA) and NYSE ADR (PHG); Exor (Agnelli family holding) is the largest shareholder: ~15% bought August 2023, above 19% during 2025 (reported); relationship-agreement cap raised from 20% to 22% on 11 August 2026
- Leadership (2026)
- Roy Jakobs, CEO (since 15 October 2022); Charlotte Hanneman, CFO; Frans van Houten was CEO 2011–2022
- Segments
- Diagnosis & Treatment (imaging, ultrasound, image-guided therapy); Connected Care (monitoring, enterprise informatics, sleep and respiratory care); Personal Health (oral care, grooming, mother and child)
- Payer and customer
- Hospitals and health systems (capital equipment, monitoring, informatics); durable medical equipment (DME) suppliers and patients for sleep and respiratory devices, paid by Medicare, commercial plans and national systems; consumers for Personal Health
- Scale
- 2025 sales €17.8bn, comparable sales growth 2% (Q4 +7%), comparable order intake +6%; adjusted EBITA margin 12.3%; free cash flow €512m after a €1,025m Respironics settlement payment (FY2025 results, 10 Feb 2026). ~64,800 employees (company, 2026)
- 2026 so far
- Guidance 3–4.5% comparable growth; adjusted EBITA margin outlook raised in July to 13.5–14.0% (including ~1 point from a US tariff refund). Q2 2026: sales ~€4.4bn, comparable +4%, order intake −1% (large orders slipped into Q3). Q3 2026 results due 3 November 2026, after this was written
- Capital / market cap
- Market cap fell from ~€45–50bn (early 2021) to ~€12–15bn (late 2022) after the recall; roughly €20–25bn in 2024–26 (approximate, from share price)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1891
Eindhoven Founding
Founding
1990
Operation Centurion
Restructuring
2008
Respironics Acquisition
Acquisition
2014
HealthTech Pivot and Lighting Separation
Divestiture / spin-off (portfolio transformation)
2021
Respironics Foam Recall
Recall
2022
Jakobs Reset and Job Cuts
Leadership change and restructuring
2023
Exor Stake
Ownership change (strategic minority investment)
2024
Consent Decree and Settlements
Regulatory settlement and litigation settlements